Avinger company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.



Loan | IPO

Total Raised


Market Cap


Stock Price




About Avinger

Avinger seeks to radically change the treatment of vascular disease through the development of new technology and a new approach called lumivascular (lumi = light, vascular = artery). Lumivascular procedures use an interventional catheter system that incorporates light-based, radiation-free, intravascular imaging technology within the actual therapeutic device. This provides physicians with live, real-time, video-rate images of the inside of an artery during treatment, offering a variety of benefits for patients, physicians and hospitals.

Avinger Headquarter Location

400 Chesapeake Drive

Redwood City, California, 94063,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Avinger

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Avinger is included in 2 Expert Collections, including Medical Devices.


Medical Devices

11,392 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

Avinger Patents

Avinger has filed 71 patents.

The 3 most popular patent topics include:

  • Medical equipment
  • Vascular diseases
  • Vascular procedures
patents chart

Application Date

Grant Date


Related Topics




Vascular diseases, Cardiology, Medical equipment, Angiology, Pseudoscience


Application Date


Grant Date



Related Topics

Vascular diseases, Cardiology, Medical equipment, Angiology, Pseudoscience



Latest Avinger News

Avinger stock climbs premarket on launch of Lightbox 3 imaging console

Apr 19, 2022

FG Trade/E+ via Getty Images Avinger (NASDAQ: AVGR ) stock climbed 11.2% premarket on Tuesday after the medical device maker announced the full commercial launch of its Lightbox 3 imaging console. AVGR conducted a limited launch of the Lightbox 3 in Feb. and Mar. This validated a mobile strategy option, through which a single highly portable Lightbox 3 can be deployed across multiple hospital sites. This strategy aims to increase AVGR's field teams' productivity, accelerate the launch of new user sites and reduce sales cycle time. "We believe the significant clinical benefits of our proprietary intravascular image-guided system, combined with the portability and reduced cost of the Lightbox 3, will accelerate new account acquisition," said AVGR CEO Jeff Soinski. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Avinger Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Avinger Rank

  • Where is Avinger's headquarters?

    Avinger's headquarters is located at 400 Chesapeake Drive, Redwood City.

  • What is Avinger's latest funding round?

    Avinger's latest funding round is Loan.

  • How much did Avinger raise?

    Avinger raised a total of $129.29M.

  • Who are the investors of Avinger?

    Investors of Avinger include Paycheck Protection Program and Lucas Venture Group.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.